Europeans Tighten Drug Safety By Monitoring Active Ingredients
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA publishes a list of active ingredients that must be monitored by European Union countries as part of efforts there to improve interstate communication and drug safety.
You may also be interested in...
European Pharmacovigilance Update Still Causing Concern
The European pharma industry understands the need to tighten EU pharmacovigilance rules, but increased powers for a new advisory and assessment body could signal trouble ahead.
France's Agency Chief Quits Over Servier Drug Safety Furor
Jean Marimbert's resignation over the Mediator affair also highlights larger issues of regulatory transparency and better pharmacovigilance.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.